The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 08, 2019

Filed:

Dec. 20, 2012
Applicant:

Yeda Research and Development Co. Ltd., Rehovot, IL;

Inventors:

Yair Reisner, Old Jaffa, IL;

Esther Bachar-Lustig, Rehovot, IL;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/28 (2015.01); A61K 35/17 (2015.01); A61K 35/22 (2015.01); A61K 35/38 (2015.01); A61K 35/39 (2015.01); A61K 35/407 (2015.01); A61K 35/42 (2015.01); A61K 31/675 (2006.01); A61K 31/661 (2006.01); A61K 35/34 (2015.01); A61K 35/36 (2015.01); C12N 5/00 (2006.01); A61K 31/198 (2006.01); A61K 31/255 (2006.01); A61K 31/7076 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 35/12 (2015.01);
U.S. Cl.
CPC ...
A61K 35/28 (2013.01); A61K 31/198 (2013.01); A61K 31/255 (2013.01); A61K 31/661 (2013.01); A61K 31/675 (2013.01); A61K 31/7076 (2013.01); A61K 35/22 (2013.01); A61K 35/34 (2013.01); A61K 35/36 (2013.01); A61K 35/38 (2013.01); A61K 35/39 (2013.01); A61K 35/407 (2013.01); A61K 35/42 (2013.01); A61K 39/3955 (2013.01); C12N 5/0087 (2013.01); A61K 2035/124 (2013.01); A61K 2039/507 (2013.01); A61K 2039/515 (2013.01);
Abstract

A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoetic cells, wherein the T cell depleted immature hematopoetic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×106 CD34+ cells per kilogram body weight of the subject, and wherein the T cell depleted immature hematopoetic cells are obtained by separating the T cells from the immature hematopoetic cells by magnetic cell sorting, and (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per body weight, thereby treating the subject.


Find Patent Forward Citations

Loading…